Literature DB >> 12802920

Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients.

Pier Luigi Zinzani1, Monica Tani, Annalisa Gabriele, Venerino Poletti, Vittorio Stefoni, Lapo Alinari, Gerardo Musuraca, Francesca Bonifazi, Stefano Pileri, Sante Tura, Michele Baccarani.   

Abstract

The lung is a relatively rare site for mucosa-associated lymphoid tissue (MALT) lymphomas: we report the largest available single-center series of patients with this presentation. From August 1992 to October 2000, 12 patients with untreated primary low-grade MALT lymphoma of the lung were submitted either to chemotherapy alone (n = 8), surgery alone (n = 2) or surgery plus chemotherapy (n = 2). At diagnosis, 6 (50%) were asymptomatic and 6 (50%) had nonspecific pulmonary symptoms. The most common radiologic findings were a pulmonary infiltrate (7 cases) and a mass lesion (5 cases). Histological diagnosis was obtained with transbronchial lung biopsy/bronchoalveolar lavage (BAL) (6 cases), with transthoracic needle biopsy (1 case), or an open thoracotomy (5 cases). All patients had stage IE. All 12 (100%) achieved complete remission; 3 (25%) local recurrences were observed. The global 6-year survival rate was 100% with a relapse-free survival rate of 50%. In conclusion, these data underline the diagnostic utility of BAL and the therapeutic efficacy of a chemotherapeutic strategy based on regimens such as N-CVP in the context of localized MALT lymphoma of the lung.

Entities:  

Mesh:

Year:  2003        PMID: 12802920     DOI: 10.1080/1042819031000067972

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  14 in total

1.  Pulmonary MALT Lymphoma in Patients with Sjögren's Syndrome.

Authors:  Ralph Yachoui; Chady Leon; Kajal Sitwala; Mazen Kreidy
Journal:  Clin Med Res       Date:  2017-05-09

2.  A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma.

Authors:  Zheng Wei; Jing Li; Zhixiang Cheng; Ling Yuan; Peng Liu
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

Review 3.  Forty years literature review of primary lung lymphoma.

Authors:  Haralabos Parissis
Journal:  J Cardiothorac Surg       Date:  2011-03-03       Impact factor: 1.637

4.  Effects of microvascular density on primary pulmonary non-Hodgkin's lymphoma (PPL).

Authors:  Maopeng Yang; Shu Zhao; Xaiosan Zhang; Xiaohong Wang; Minghui Zhang; Yan Wang; Qingyuan Zhang
Journal:  Tumour Biol       Date:  2012-08-09

5.  Prolonged complete remission in a primary MALT lymphoma of the lung after rituximab monotherapy.

Authors:  M D Diamantidis; S Chatzileontiadou; D Pantelidou; M Papaioannou
Journal:  Hippokratia       Date:  2017 Apr-Jun       Impact factor: 0.471

6.  Imaging manifestations of autoimmune disease-associated lymphoproliferative disorders of the lung.

Authors:  Geewon Lee; Ho Yun Lee; Kyung Soo Lee; Kyung Jong Lee; Hoon-Suk Cha; Joungho Han; Man Pyo Chung
Journal:  Clin Rheumatol       Date:  2013-06-02       Impact factor: 2.980

7.  Decision-making in diagnosis of bronchus-associated lymphoid tissue lymphoma.

Authors:  Tasnim Lat; Juan F Sanchez; Meghan K McGraw; Parsa Hodjat; Heath D White; Carl D Boethel
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-03-09

8.  Primary pulmonary lymphoma and cutaneous metastasis: a case report.

Authors:  Ali Latif Moini; Tahmineh Farbod Ara; Masood Fazeli Mosleh Abadi
Journal:  Iran J Radiol       Date:  2014-08-01       Impact factor: 0.212

9.  Primary pulmonary lymphoma: About five cases and literature review.

Authors:  Noura Majid; El Bakraoui Kamal; Boukir Oncology; Aassab Rachid; Inrhaoun Hannane Errihani Hassan
Journal:  Lung India       Date:  2014-01

10.  Clinical manifestations of pulmonary mucosa-associated lymphoid tissue lymphoma: single-center experience with 18 patients.

Authors:  Shasha Zhao; Lin Zhang; Zhenyang Gu; Chengying Zhu; Shu Fang; Nan Yang; Feiyan Wang; Lixun Guan; Lan Luo; Chunji Gao
Journal:  Onco Targets Ther       Date:  2018-01-24       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.